Eli Lilly and Company reaffirmed its earnings guidance for the year 2012. The company previously published 2012 earnings per share guidance in the range of $3.68 to $3.78 on a reported basis, or $3.30 to $3.40 on a non-GAAP basis when excluding $0.43 per share of income from the early payment of Amylin's exenatide revenue sharing obligation and $0.05 per share of asset impairment and restructuring charges through the first nine months of 2012.

For 2013, the company expects earnings per share to be in the range of $4.03 to $4.18 on a reported basis, or $3.75 to $3.90 on a non-GAAP basis when excluding an estimated $0.28 per share of exenatide-related income contingent upon the transfer of exenatide commercial rights outside the U.S. to Amylin. The company anticipates 2013 revenue of between $22.6 billion and $23.4 billion. On a reported basis, the 2013 tax rate is expected to be approximately 22.5%, assuming a full-year 2013 benefit of the R&D tax credit. On a non-GAAP basis, the 2013 tax rate is expected to be approximately 21%. Operating cash flows are expected to be more than sufficient to allow for capital expenditures of approximately $900 million.

From now through 2014, on an annual basis the company still expects revenue to be at least $20 billion, net income to be at least $3 billion, and operating cash flow to be at least $4 billion.